Selling new drugs is becoming a problem for drugmakers despite the quickest pace for launches since the 1990s, according to this article. Drugmakers are having a difficult time demonstrating to insurers, doctors and patients that new treatments justify what can be premium prices. Drugs targeted at diseases with already effective medications are facing high skepticism.

Related Summaries